Research Topics
| O BrattSummaryAffiliation: Lund University Country: Sweden Publications
| Collaborators |
Detail Information
Publications
Clinical course of early onset prostate cancer with special reference to family history as a prognostic factorO Bratt
Department of Urology, Lund University Hospital, Sweden
Eur Urol 34:19-24. 1998..The aim of this study was to describe the clinical characteristics of early onset prostate cancer, with special reference to family history as a possible prognostic factor...
Familial and hereditary prostate cancer in southern Sweden. A population-based case-control studyO Bratt
Department of Urology, Lund University Hospital, Sweden
Eur J Cancer 35:272-7. 1999..Furthermore, we found self-reported family history of prostate cancer to be a valid estimate of the true incidence of prostate cancer in fathers and brothers of men with prostate cancer...
Risk perception, screening practice and interest in genetic testing among unaffected men in families with hereditary prostate cancerO Bratt
Department of Urology, University of Lund, Sweden
Eur J Cancer 36:235-41. 2000..The present study underlines the importance of giving thorough, repeated information to men at high risk of prostate cancer...
CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer riskO Bratt
Department of Urology, University of Lund, Sweden
Br J Cancer 81:672-6. 1999..An association between long CAG repeats and good response to endocrine therapy was also found, but the mechanism and clinical relevance are unclear...
Hereditary prostate cancer: clinical characteristics and survivalO Bratt
Unit for Urology, Helsingborg Hospital, Department of Urology, Sahlgrenska University Hospital, Gothenburg, Sweden
J Urol 167:2423-6. 2002..However, it cannot be excluded that individual hereditary prostate cancer genes may have specific biological characteristics...
Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancerO Bratt
Department of Urology, Helsingborg Hospital, Lund University, SE 25187 Helsingborg, Sweden
Br J Cancer 101:1233-40. 2009..Two open-label phase I clinical trials in patients were conducted to evaluate the safety and tolerability of tasquinimod, with additional pharmacokinetic and efficacy assessments...
